




KMCH Institute of Health sciences and Research Coimbatore, Department of Pharmacology New Drug Update

October 2021

Series 27

In This Series

- Biosimilars
- Antibody drug conjugate -CA cervix
- Novel Formulations
- New drugs -Migraine



Approved drugs

1. Maralixibat
2. Atogepant
3. Ruxolitinib
4. Tisotumab Vedotin-tftv
5. Ranibizumab-nuna
6. Mobocertinib
7. Dihydroergotamine Mesylate

1. Maralixibat

DATE OF APPROVAL: Sep 29, 2021

MECHANISM OF ACTION: Ilean bile acid transporter (IBAT) inhibitor

INDICATION: Cholestatic pruritus in patients with Alagille syndrome aged 1 year and older

DOSAGE FORM: Oral solution

2. Atogepant

DATE OF APPROVAL: Sep 28, 2021

MECHANISM OF ACTION: Calcitonin gene-related peptide receptor antagonist

INDICATION: Preventive treatment of episodic migraine in adults

DOSAGE FORM: Tablets, for oral use

3. Ruxolitinib

DATE OF APPROVAL: Sep 21, 2021

MECHANISM OF ACTION: Janus kinase (JAK) inhibitor

INDICATION: Short-term & non-continuous chronic treatment of mild to moderate atopic dermatitis in non-immunocompromised patients aged 12 years and older, when disease is not controlled with topical therapies / not advisable

DOSAGE FORM: Cream, for topical use

4. Tisotumab Vedotin-tftv

DATE OF APPROVAL: September 20, 2021

MECHANISM OF ACTION: Tissue factor-directed antibody and microtubule inhibitor conjugate

INDICATION: Adult patients with recurrent or metastatic cervical cancer with disease progression on or after chemotherapy

DOSAGE FORM: Lyophilized Powder for Intravenous Infusion

5. Ranibizumab-nuna

DATE OF APPROVAL: September 17, 2021

MECHANISM OF ACTION: Vascular endothelial growth factor inhibitor biosimilar that prevents vision loss in patients with retinal vascular disorders

INDICATION: Neovascular (wet) age-related macular degeneration, macular edema following retinal vein occlusion and myopic choroidal neovascularization

DOSAGE FORM: Intravitreal Injection

6. Mobocertinib

DATE OF APPROVAL: September 15, 2021

MECHANISM OF ACTION: An oral tyrosine kinase inhibitor

INDICATION: Adult patients with epidermal growth factor receptor exon20 insertion mutation-positive metastatic non-small cell lung cancer

DOSAGE FORM: Capsules for oral use

7. Dihydroergotamine Mesylate

DATE OF APPROVAL: Sep 2, 2021

MECHANISM OF ACTION: Ergotamine derivative that causes vasoconstriction by acting on 5-HT_{1D} receptors present in intracranial blood vessels, including those on arterio-venous anastomoses and leads to vasoconstriction & provides relief of migraine headache

INDICATION: Acute treatment of migraine with or without aura in adults

DOSAGE FORM: Nasal spray

CONTACT US:

Department of
Pharmacology,
KMCHHSR,
Coimbatore-
641014

Email:
hodpharmacology
@kmchhsr.edu.in

